{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Everolimus for Belatacept-Refractory Renal Allograft Rejection"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomised controlled trial, peripheral mononuclear cells, serum creatinine levels, and renal biopsies were collected from 8 patients"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "mTOR inhibition with everolimus"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine the mechanisms and treatment of rejection in kidney transplant recipients under belatacept-based early corticosteroid withdrawal following T cell depleting induction."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "8 patients"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Everolimus treatment halted the in vivo proliferation of T_EM cells, reduced their ex vivo alloreactivity, and significantly decreased their presence in peripheral blood."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: clinicaltrials.gov #NCT01729494."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 9,
    "max_score": 25
  },
  "model": "gpt-4o"
}